Fulgent Genetics Stock Today
| FLGT Stock | USD 20.56 0.20 0.98% |
Performance0 of 100
| Odds Of DistressLess than 8
|
Fulgent Genetics is selling for under 20.56 as of the 23rd of April 2024; that is 0.98 percent up since the beginning of the trading day. The stock's last reported lowest price was 20.26. Fulgent Genetics has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Fulgent Genetics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of March 2024 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 29th of September 2016 | Category Healthcare | Classification Health Care |
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. The company has 29.9 M outstanding shares of which 603.98 K shares are currently shorted by private and institutional investors with about 2.23 trading days to cover. More on Fulgent Genetics
Moving together with Fulgent Stock
| 0.84 | DH | Definitive Healthcare Financial Report 2nd of May 2024 | PairCorr |
| 0.89 | GH | Guardant Health Upward Rally | PairCorr |
| 0.92 | FIGS | Figs Inc Financial Report 2nd of May 2024 | PairCorr |
Moving against Fulgent Stock
| 0.88 | WGS | GeneDx Holdings Corp Earnings Call This Week | PairCorr |
| 0.79 | GCTK | GlucoTrack | PairCorr |
| 0.63 | RCM | R1 RCM Inc Financial Report 2nd of May 2024 | PairCorr |
| 0.5 | HQY | HealthEquity Financial Report 3rd of June 2024 | PairCorr |
| 0.44 | FORA | Forian Inc Financial Report 10th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 3rd of May 2024
Fulgent Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Fulgent Genetics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Fulgent Genetics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Ming Hsieh | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Providers & Services, Health Care Equipment & Services, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Health Care, Healthcare, Health Care, Health Care Providers & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Fulgent Genetics report their recommendations after researching Fulgent Genetics' financial statements, talking to executives and customers, or listening in on Fulgent Genetics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Fulgent Genetics. The Fulgent consensus assessment is calculated by taking the average forecast from all of the analysts covering Fulgent Genetics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Fulgent Genetics' liquidity, profitability, solvency, and operating efficiency, Fulgent Genetics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Fulgent Genetics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fulgent Genetics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Fulgent Genetics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Fulgent Genetics' financial leverage. It provides some insight into what part of Fulgent Genetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fulgent Genetics (FLGT) is traded on NASDAQ Exchange in USA. It is located in 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 and employs 1,184 people. Fulgent Genetics is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 608.78 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fulgent Genetics's market, we take the total number of its shares issued and multiply it by Fulgent Genetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Fulgent Genetics conducts business under Health Care Providers & Services sector and is part of Health Care industry. The entity has 29.9 M outstanding shares of which 603.98 K shares are currently shorted by private and institutional investors with about 2.23 trading days to cover.
Fulgent Genetics currently holds about 515.4 M in cash with 27 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.03.
Check Fulgent Genetics Probability Of Bankruptcy
Ownership AllocationFulgent Genetics retains a total of 29.9 Million outstanding shares. Fulgent Genetics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Fulgent Ownership Details
Fulgent Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Fulgent Genetics jumping above the current price in 90 days from now is about 92.98%. The Fulgent Genetics probability density function shows the probability of Fulgent Genetics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4913. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Fulgent Genetics will likely underperform. Additionally, fulgent Genetics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Fulgent Genetics to move above the current price in 90 days from now is about 92.98 (This Fulgent Genetics probability density function shows the probability of Fulgent Stock to fall within a particular range of prices over 90 days) .
Fulgent Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Fulgent Genetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fulgent Genetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fulgent Genetics' value.| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 263.3 K | |
| Ameriprise Financial Inc | 2023-12-31 | 250.6 K | |
| Northern Trust Corp | 2023-12-31 | 231.4 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 204.8 K | |
| Citadel Advisors Llc | 2023-09-30 | 193 K | |
| Norges Bank | 2023-12-31 | 176.5 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 155.9 K | |
| Bridgeway Capital Management, Llc | 2023-12-31 | 153.7 K | |
| Divisadero Street Capital Management, Lp | 2023-12-31 | 137.3 K | |
| Blackrock Inc | 2023-12-31 | 3.8 M | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 1.4 M |
Fulgent Genetics Historical Income Statement
Fulgent Genetics Income Statement is one of the three primary financial statements used for reporting Fulgent's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Fulgent Genetics revenue and expense. Fulgent Genetics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Fulgent Genetics' Cost Of Revenue is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 180.5 M in 2024, despite the fact that Net Loss is likely to grow to (61.7 M). View More FundamentalsFulgent Stock Against Markets
Picking the right benchmark for Fulgent Genetics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Fulgent Genetics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Fulgent Genetics is critical whether you are bullish or bearish towards Fulgent Genetics at a given time. Please also check how Fulgent Genetics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Fulgent Genetics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Fulgent Genetics Corporate Directors
Fulgent Genetics corporate directors refer to members of a Fulgent Genetics board of directors. The board of directors generally takes responsibility for the Fulgent Genetics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Fulgent Genetics' board members must vote for the resolution. The Fulgent Genetics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| James Mulay | Director | Profile | |
| Linda Marsh | Director | Profile | |
| John Bolger | Director | Profile | |
| Hanlin Gao | Lab Director and Chief Scientific Officer | Profile |
How to buy Fulgent Stock?
Before investing in Fulgent Genetics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Fulgent Genetics. To buy Fulgent Genetics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Fulgent Genetics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Fulgent Genetics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Fulgent Genetics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Fulgent Genetics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Fulgent Genetics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.
Already Invested in Fulgent Genetics?
The danger of trading Fulgent Genetics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Fulgent Genetics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Fulgent Genetics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Fulgent Genetics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Fulgent Genetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Fulgent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Fulgent Genetics Stock. Highlighted below are key reports to facilitate an investment decision about Fulgent Genetics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.